Invivyd (NASDAQ: IVVD) is a leading biotechnology company that focuses on developing antibody treatments to fight serious viral diseases. Its main commercial product is PEMGARDA, an antibody used for the pre-exposure prevention of COVID-19 in certain individuals. The company is also advancing other antibody candidates through clinical trials.
On May 14, 2026, Invivyd reported its first-quarter financial results. The company announced an earnings per share (EPS) of -$0.13. This figure represents the company's net profit or loss divided by its number of shares. The result missed the analyst consensus estimate of -$0.08 per share.
The company's revenue for the quarter was $13.74 million, which also fell short of the estimated $18.04 million. As highlighted by Zacks Investment Research, this is the third time in the last four quarters that Invivyd has missed consensus revenue estimates.
Despite missing estimates, the financial results show some year-over-year progress. The quarterly loss of $0.13 per share is a slight improvement from the loss of $0.14 per share reported a year ago. Net product revenue from PEMGARDA grew 22% from $11.30 million in the first quarter of 2025.
The company’s increased losses are linked to higher clinical development spending. Operating expenses grew due to costs for the pivotal DECLARATION study for VYD2311, a new antibody candidate. Invivyd ended the quarter with a cash balance of $184.20 million to fund its ongoing operations.
